![Robert Sterling](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert Sterling
Plus aucun poste en cours
Profil
Robert Sterling is Vice President of Business Development for Bioenvision, Inc. Prior to joining Bioenvision in December, 2001, he held various marketing and sales positions at Hoechst Roussel Vet Gmbh.
Mr. Sterling received a BS degree from Pennsylvania State University.
Anciens postes connus de Robert Sterling
Sociétés | Poste | Fin |
---|---|---|
Hoechst Roussel Vet Gmbh
![]() Hoechst Roussel Vet Gmbh Pharmaceuticals: OtherHealth Technology Part of Merck & Co., Inc., Hoechst Roussel Vet Gmbh develops pharmaceutical products for animals. The company is based in Hessen, Germany. Hoechst Roussel Vet was acquired by Intervet International BV from Hoechst AG on August 11, 1999 for $713.99 million. | Corporate Officer/Principal | - |
Bioenvision, Inc.
![]() Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Formation de Robert Sterling
The Pennsylvania State University | Undergraduate Degree |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 2 |
---|---|
Bioenvision, Inc.
![]() Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | Health Services |
Hoechst Roussel Vet Gmbh
![]() Hoechst Roussel Vet Gmbh Pharmaceuticals: OtherHealth Technology Part of Merck & Co., Inc., Hoechst Roussel Vet Gmbh develops pharmaceutical products for animals. The company is based in Hessen, Germany. Hoechst Roussel Vet was acquired by Intervet International BV from Hoechst AG on August 11, 1999 for $713.99 million. | Health Technology |